|
1
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meza-Junco J, Montano-Loza AJ, Liu DM,
Sawyer MB, Bain VG, Ma M and Owen R: Locoregional radiological
treatment for hepatocellular carcinoma; Which, when and how? Cancer
Treat Rev. 38:54–62. 2012. View Article : Google Scholar
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bruix J, Raoul JL, Sherman M, Mazzaferro
V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M,
Sangiovanni A, et al: Efficacy and safety of sorafenib in patients
with advanced hepatocellular carcinoma: Subanalyses of a phase III
trial. J Hepatol. 57:821–829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wada J, Ota K, Kumar A, Wallner EI and
Kanwar YS: Developmental regulation, expression, and apoptotic
potential of galectin-9, a beta-galactoside binding lectin. J Clin
Invest. 99:2452–2461. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabinovich GA, Liu FT, Hirashima M and
Anderson A: An emerging role for galectins in tuning the immune
response: Lessons from experimental models of inflammatory disease,
autoimmunity and cancer. Scand J Immunol. 66:143–158. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagahara K, Arikawa T, Oomizu S, Kontani
K, Nobumoto A, Tateno H, Watanabe K, Niki T, Katoh S, Miyake M, et
al: Galectin-9 increases Tim-3+ dendritic cells and
CD8+ T cells and enhances antitumor immunity via
galectin-9-Tim-3 interactions. J Immunol. 181:7660–7669. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33(Suppl 1): E102–E126. 2013. View Article : Google Scholar
|
|
12
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M, et al: Targeting activating transcription factor 3 by Galectin-9
induces apoptosis and overcomes various types of treatment
resistance in chronic myelogenous leukemia. Mol Cancer Res.
8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang ZY, Dong JH, Chen YW, Wang XQ, Li
CH, Wang J, Wang GQ, Li HL and Wang XD: Galectin-9 acts as a
prognostic factor with antimetastatic potential in hepatocellular
carcinoma. Asian Pac J Cancer Prev. 13:2503–2509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X,
Liu J, Shi L, Liu C, Wang G, et al: Tim-3/galectin-9 signaling
pathway mediates T-cell dysfunction and predicts poor prognosis in
patients with hepatitis B virus-associated hepatocellular
carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nishikawa T, Nakajima T, Moriguchi M, Jo
M, Sekoguchi S, Ishii M, Takashima H, Katagishi T, Kimura H, Minami
M, et al: A green tea polyphenol, epigalocatechin-3-gallate,
induces apoptosis of human hepatocellular carcinoma, possibly
through inhibition of Bcl-2 family proteins. J Hepatol.
44:1074–1082. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kashio Y, Nakamura K, Abedin MJ, Seki M,
Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol.
170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin SJ, Reutelingsperger CP, McGahon
AJ, Rader JA, van Schie RC, LaFace DM and Green DR: Early
redistribution of plasma membrane phosphatidylserine is a general
feature of apoptosis regardless of the initiating stimulus:
Inhibition by overexpression of Bcl-2 and Abl. J Exp Med.
182:1545–1556. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The anti-diabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kobayashi M, Kato K, Iwama H, Fujihara S,
Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, et al:
Antitumor effect of metformin in esophageal cancer: In vitro study.
Int J Oncol. 42:517–524. 2013.
|
|
23
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Workman P, Aboagye EO, Balkwill F, Balmain
A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA,
Glennie MJ, et al: Committee of the National Cancer Research
Institute: Guidelines for the welfare and use of animals in cancer
research. Br J Cancer. 102:1555–1577. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tamura T, Fujita F, Tanimoto M, Koike M,
Suzuki A, Fujita M, Horikiri Y, Sakamoto Y, Suzuki T and Yoshino H:
Anti-tumor effect of intraperitoneal administration of
cisplatin-loaded microspheres to human tumor xenografted nude mice.
J Control Release. 80:295–307. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the anti-diabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
27
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rao RV, Ellerby HM and Bredesen DE:
Coupling endoplasmic reticulum stress to the cell death program.
Cell Death Differ. 11:372–380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Liao JM, Zeng SX and Lu H: p53
downregulates Down syndrome-associated DYRK1A through miR-1246.
EMBO Rep. 12:811–817. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Asghar U and Meyer T: Are there
opportunities for chemotherapy in the treatment of hepatocellular
cancer? J Hepatol. 56:686–695. 2012. View Article : Google Scholar
|
|
31
|
Callegari E, Elamin BK, Sabbioni S,
Gramantieri L and Negrini M: Role of microRNAs in hepatocellular
carcinoma: A clinical perspective. Onco Targets Ther. 6:1167–1178.
2013.PubMed/NCBI
|
|
32
|
Nobumoto A, Nagahara K, Oomizu S, Katoh S,
Nishi N, Takeshita K, Niki T, Tominaga A, Yamauchi A and Hirashima
M: Galectin-9 suppresses tumor metastasis by blocking adhesion to
endothelium and extracellular matrices. Glycobiology. 18:735–744.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kerr TA, Korenblat KM and Davidson NO:
MicroRNAs and liver disease. Transl Res. 157:241–252. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kushibiki T, Hirasawa T, Okawa S and
Ishihara M: Regulation of miRNA expression by low-level laser
therapy (LLLT) and photodynamic therapy (PDT). Int J Mol Sci.
14:13542–13558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bach D, Fuereder J, Karbiener M,
Scheideler M, Ress AL, Neureiter D, Kemmerling R, Dietze O,
Wiederstein M, Berr F, et al: Comprehensive analysis of alterations
in the miRNome in response to photodynamic treatment. J Photochem
Photobiol B. 120:74–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Deng L, Ren Z, Jia Q, Wu W, Shen H and
Wang Y: Schedule-dependent antitumor effects of 5-fluorouracil
combined with sorafenib in hepatocellular carcinoma. BMC Cancer.
13:3632013. View Article : Google Scholar : PubMed/NCBI
|
